Loading…
Takeda will invest €100 million by 2025 in its Linz, Austria production site, including a new syringe production line for biologics treating chronic inflammatory bowel diseases. The line is expected to start production in fiscal year 2024.
“Bis zum Jahr 2025 will Arzneimittelhersteller Takeda 100 Millionen Euro in den Produktionsstandort Linz investieren, um den langfristigen Fokus auf die Herstellung von Biologika zur Behandlung chronisch entzündlicher Darmerkrankungen weiter zu stärken.”tips.at
Summarized from public sources; check the original articles before acting on it.